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INTRODUCTION
Radical cystectomy is considered the standard treatment for
muscle-invasive bladder cancer, and over recent years surgical
techniques have improved and urinary diversion has been intro-
duced, which have undoubtedly improved quality of life. How-
ever, even the construction of a neobladder with continent uri-
nary diversion cannot substitute for the original bladder. Resul-
tantly, trimodality treatment, including transurethral resec-
tion of bladder tumor (TURBT) and chemoradiotherapy (CRT)
has been suggested as a bladder-preserving therapy in invasive
bladder cancer over the past two decades (1-4). To my knowl-
edge, no study has been reported on a prospectively designed
trimodality protocol for muscle-invasive bladder cancer in
Korean patients. To determine the clinical effectiveness of
this trimodality treatment, we designed the present study of
concurrent CRT incorporating cisplatin following TURBT
for the treatment of muscle-invasive bladder cancer.
MATERIALS AND METHODS
Patient selection
Patient with cT2-3 bladder cancer and an eastern cooper-
ative oncology group (ECOG) of <2 were enrolled in this
study. Initial evaluations included chest radiography, com-
puted tomography (CT) scan of abdomen and pelvis, com-
plete blood count (CBC) and serum chemistry, and creati-
nine clearance. A white blood cell (WBC) of >4,000/μ L, a
platelet count of >100,000/μ L, bilirubin <1.5 mL/dL, and a
creatinine clearance of >60 mL/min were mandatory. Patients
were excluded if there was evidence of distant metastases, or
prior pelvic irradiation, or if cisplatin chemotherapy was con-
traindicated.
A trimodality treatment was recommended as an alterna-
tive treatment to radical cystectomy only to patients who un-
derwent complete TURBT. On the other hand, radical cys-
tectomy was strongly recommended as a standard treatment to
patients if complete TURBT was deemed impossible. When
patients refused to undergo an operation designed to remove
the native bladder, they were considered for the present study.
After giving written informed consent, patients were enrolled
for the concurrent CRT protocol, which was initiated 3-4 weeks
after TURBT.
Treatment protocol
TURBT
TURBT was performed layer by layer, which produced three
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Single Institutional Experience of Bladder-Preserving Trimodality
Treatment for Muscle-Invasive Bladder Cancer
The authors designed this study to determine the clinical effectiveness of trimodality
treatment, i.e., transurethral resection of a bladder tumor (TURBT) and concurrent
chemoradiotherapy (CRT). Twenty patients with a muscle-invasive bladder cancer
were treated by TURBT followed by concurrent cisplatin (75 mg/m
2 day), adminis-
tered on weeks 1 and 4 of radiotherapy. According to residual tumor status after
TURBT, patients were classified into patients with a complete TURBT group and
incomplete TURBT group. Response to treatment was evaluated by restaging
TURBT at 4 weeks after completing CRT (post-CRT). Fifteen patients (75%) achiev-
ed complete remission (CR) at restaging; 10 patients (50%) remained continuous-
ly free of tumor recurrence. Disease-specific and overall survivals were 51.1% and
38.6% at 5 yr post-CRT, respectively. Of 16 patients in the complete TURBT group,
14 patients (87.5%) achieved CR, which was significantly different from that observed
in the incomplete TURBT group, in which only 1 (25%) of 4 patients achieved CR
(p=0.032). Five- year disease-specific and overall survivals were 71.6% and 53.5%,
respectively. Ten patients (90.9%) maintained their own bladder among the 11
surviving patients. Trimodality treatment was found to be an effective treatment in
patients who underwent complete TURBT for a muscle-invasive bladder cancer.
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separate specimen groups according to depth, i.e., the super-
ficial layer from mucosa and submucosa, deep layer from super-
ficial muscle, and a bottom layer from deep muscle. Complete-
ness of TURBT was assessed according to residual tumor sta-
tus. Tumor infiltration in the deep layer with no tumor infil-
tration in the bottom layer was defined as microscopic no resid-
ual tumor. Scant tumor infiltration (up to 2 foci per high power
field, ×400) in the bottom layer and prominent tumor infil-
tration in the deep layer was defined as microscopic residual
tumor, and gross residual tumor on the resection surface or
prominent tumor infiltration even in the bottom layer was
defined macroscopic residual tumor. Therefore, complete
TURBT was defined as microscopic no residual tumor or mi-
croscopic residual tumor, whereas incomplete TURBT was
defined as macroscopic residual tumor.
Concurrent chemoradiotherapy
Radiotherapy was initiated 3-4 weeks after TURBT using
6- to 10-MV photons and a four-field box technique with
individually shaped portals and daily fractions of 1.8 Gy on
5 consecutive days. Planned target volumes (PTV) consisted
of the bladder and tumor with a 2-cm contoured margin. PTV
were sometimes modified after administering a dose of 40 or
45 Gy and a cone down boost was given to exclude the unin-
volved part of the bladder, provided the tumor was unifocal
and well lateralized. The total dose given during the induc-
tion period was 45 Gy in 1.8 Gy daily fractions over 5 weeks
and 20 Gy in 1.8 Gy daily fractions over 2 weeks during the
consolidation period. Therefore, total doses administered to
whole bladder and pelvic lymph node ranged from 45 and
65 Gy. As concurrent chemotherapy, cisplatin 75 mg/m2 was
administered by slow intravenous infusion in conjunction with
adequate hydration on weeks 1 and 4 of radiotherapy.
Response evaluation and salvage treatment
Four weeks after completing CRT (post-CRT), initial res-
ponse was evaluated by restaging TURBT of the former tumor
region, and by urine cytology and CT. Complete remission
was diagnosed when no evidence of residual tumor was found
on restaging TURBT, no cancer cells were found by urine
cytology, and there was no evidence of tumor recurrence by
CT. Patients were regarded as having local failure if they had
superficial recurrence or persistent invasive cancer by restag-
ing TURBT at 4 weeks post-CRT, and were regarded as hav-
ing distant failure if they had developed metastasis by CT. In
case of persistent invasive cancer at initial evaluation after CRT,
salvage cystectomy was preferentially recommended.
Follow-up schedules
In case of complete response at 4 weeks post-CRT, patients
were followed up at 3-months intervals by CT, urine cytolo-
gy, and by cystoscopic biopsy (the latter was performed when
cystoscopic findings were suspicious). Follow-up was performed
on a 3 monthly basis for the first 3 yr, 6 monthly for the next
3 yr, and then annually. In addition, acute hematologic and
non-hematologic toxicities were assessed weekly during CRT
according to the National Cancer Institute Common Toxic-
ity Criteria, version 2.0, and late complications were noted
during follow-up.
End points and statistical analysis
The major statistical endpoints of this study were; the CR
rate at 4 weeks post-CRT, disease-specific survival (DSS) at
5 yr, and overall survival (OS) at 5 yr. Actuarial survival rates
were calculated from the end of CRT to the time of the last
follow-up visit or death, using the Kaplan-Meier method. The
Mann-Whitney U test was used to analyze continuous variable
and the chi-square or Fisher’s exact tests were used to analyze
categorical variables. Statistical significance was accepted at
the p<0.05 (two-sided) level. Statistical analysis was performed
entirely using the Statistical Package for the Social Sciences
for Windows, version 11 (SPSS Inc, Chicago, IL, U.S.A.).
RESULTS
Patient characteristics
From March 2000 to January 2006, 22 patients with mus-
cle-invasive cT2-3 bladder cancer were enrolled in this prospec-
tive study. Of these, 20 patients completed the CRT protocol
and two patients were excluded because they refused to con-
tinue with the study protocol during radiotherapy induction
in the absence of complications. CRT was actively recommend-
ed as an alternative treatment to radical cystectomy in 16 pa-
WHO, World Health Organization; CIS, carcinoma in situ.
Variables No. of patients (%)
Male vs. female 11 (55) vs. 9 (45)
Primary tumor 10 (50)
Recurrent tumor 10 (50)
Tumor size
<5 cm 8 (40)
≥5 cm 12 (60)
Multiplicity
Single 10 (50)
Multiple 10 (50)
Clinical stage
T2N0M0 12 (60)
T3N0M0 8 (40)
Grade (WHO grade)
1-2 4 (20)
3 16 (80)
Associated CIS 1 (5)
Residual tumor status
No microscopic residual tumor 3 (15)
Microscopic residual tumor 13 (65)
Macroscopic residual tumor 4 (20)
Table 1. Patient characteristics (n=20)600 J.Y. Joung, K.S. Han, T.S. Kim, et al.
tients with complete TURBT. On the other hand, radical
cystectomy was preferentially recommended in 4 patients with
incomplete TURBT. However, these 4 patients strongly want
to preserve the native bladder and voluntarily enrolled in this
study. The characteristics of the 20 patients are outlined in
Table 1.
Initial response and salvage treatment
In terms of initial response at 4 weeks post-CRT, 15 patients
(75%) achieved CR and 5 patients (25%) had a persistent
invasive cancer at 4 weeks post-TURBT. In terms of response
to CRT according to the completeness of TURBT, 14 (87.5
%) of 16 patients with complete TURBT achieved CR where-
as only 1 (25%) of 4 patients with incomplete TURBT ac-
hieved CR, which was significant (p=0.032). Radical cystec-
tomy was preferentially recommended as a salvage treatment
to 5 patients who failed to achieve CR as an initial response
to CRT. However, only one patient accepted our suggestion;
the other 4 chose CMV (cisplatin, methotrexate, and vin-
blastine) chemotherapy rather than an operation.
Tumor recurrence after complete remission
Of 15 patients with CR at initial response, tumor recurrence
(both local and distant) occurred in 7 patients. Two patients
showed invasive tumor recurrence at the preserved bladder
6 months and 52 months post-CRT. The patient with later
recurrence developed a recurrent superficial cancer before an
invasive cancer. For salvage treatment of invasive cancer, both
patients requested chemotherapy rather than salvage cystec-
tomy, and they remained in a locally controlled state with no
evidence of distant metastasis by cystoscopy or CT scan at 6
months after chemotherapy using MVAC regimen. On the
other hand, isolated superficial recurrences were found in anoth-
er 2 patients. Of these, one patient experienced superficial
recurrences on three occasions, which were managed by TUR
and intravesical chemotherapy. The other patient showed expe-
rienced a single recurrence at 48 months post-CRT. In anoth-
er 3 patients, isolated distant metastases to brain, lung and
liver developed at 6, 10 and 24 months post-CRT, and under-
went MVAC (methotrexate, vinblastine, adriamycin, and cis-
platin) for the treatment of distant metastasis. Subsequently,
they died of progression to bladder cancer. Treatment out-
comes are summarized in Fig. 1.
Survival and bladder preservation
After 33 months (range, 8-62 months) of median follow-
up period for all study subjects, 9 deaths had occurred. All 4
patients with incomplete TURBT died of bladder cancer
progression at a median 12 months (range, 8-43 months)
post-CRT. On the other hand, of the 16 patients with com-
plete TURBT, 3 patients died of bladder cancer progression
and 2 of other causes (lung cancer and a heart attack). DSS
and OS rates for all 20 patients were 51.1% and 38.6% at 5
yr, respectively, and those of the 16 patients with complete
TURBT were 71.6% and 53.5%, respectively. DSS and OS
Fig. 1. Treatment outcomes. TURBT, transurethral resection of bladder tumor; CR, complete remission, PIT, persistent invasive tumor; recur,
recurrence; Ds, disease. 
Total number of patients: 20
CR
14
PIT
2
Sustained CR: 8
Invasive recur: 2
Superficial recur: 2
Distant recur: 2
Chemotherapy: 4
TURBT: 2
Survival: 10
Death: 4
Ds-specific: 2
Other causes: 2
Cystectomy: 1
Chemotherapy: 1
Survival: 1
Death: 1
TURBT Incomplete TURB: 4 Complete TURB: 4
Initial evaluation at 4 weeks after CRT
CR
1
PIT
3
Brain
metastasis
Cystectomy: 1
Chemotherapy: 2
Death: 1 Progression to death: 3Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer 601
rates showed significant differences according to the com-
pleteness of TURBT (DSS, p=0.004; OS, p=0.001) (Fig. 2).
Of the 11 surviving patients, 10 patients (90.9%) retained
their own bladders at the time of analysis.
Treatment-related toxicities
Toxicities are briefly presented in Table 2. In terms of hema-
tologic toxicities, neutropenia, leukopenia, thrombocytope-
nia, and anemia were reported in 1 (5%), 5 (25%), 2 (10%),
and 2 (10%) patients, respectively. Only one patient (5%)
required a dose reduction due to neutropenia, and recovered
within 2 weeks. In terms of non-hematologic toxicities, diar-
rhea was most frequently reported and occurred in 7 (35%)
patients. No case of grade 3-4 non-hematologic toxicity was
encountered. All patients who experienced a non-hematolog-
ic toxicity recovered with conservative treatment. In terms
of bladder function, mild dysuria, urgency, and nocturia were
registered in 20-55% of patients, but these were temporary
and improved 3 months post-CRT. No remarkable late com-
plication occurred, though one patient complained of noctur-
nal frequency due to a decreased functional bladder capacity.
DISCUSSION
Traditionally, transitional cell carcinoma (TCC) is known
to be sensitive to cisplatin-based chemotherapy (5). In addi-
tion, radiation therapy has been administered to patients who
appear to be unsuitable for radical cystectomy (6). However,
in the case of muscle-invasive bladder cancer, adequate can-
cer control cannot be achieved by TURBT, chemotherapy, or
radiotherapy alone. Over the last two decades, some centers
in the United States and Europe adopted a trimodality treat-
ment (1-4).
The rationale for combining radiotherapy with chemother-
apy after TURBT is twofold. First, certain cytotoxic agents
may have the ability to sensitize cancer cells to radiation and
to inhibit repopulation during radiotherapy. Second, high rates
of occult metastases require that efforts to eradicate occult me-
tastases that have already developed in as many as 50% of
muscle-invasive cancer (7).
There are two main concerns about CRT. The selection of
optimal regimens and ideal candidates are main issues following
bladder-preserving therapy, but optimal regimens have not
been established. In general, cisplatin and 5-FU (fluorouracil)
are still recommended by many investigators, because both
agents have been shown to have radiosensitizing activities and
acceptable toxicities (8). In addition, to these two drugs, newer
chemotherapeutic agents, particularly gemcitabine and tax-
anes, have also been shown to be potent radiation sensitizers
(9). Furthermore, recent studies have established that gemc-
itabine in combination with radiotherapy as a feasible regimen
for bladder sparing treatments, and other series have shown
that concurrent CRT using platinum and paclitaxel or doc-
Fig. 2. Kaplan-Meier estimates of likelihood of overall survival (A) and disease-specific survival (B) for patients with complete TURBT vs.
incomplete TURBT.
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Variables No. of patients (%)
Hematologic
Neutropenia 1  (5)
Leukopenia 5 (25)
Thrombocytopenia 2 (10)
Anemia 2 (10)
Non-hematologic
Diarrhea 7 (35)
Irritative voiding symptoms 11 (55)
Nausea and vomiting 2 (10)
Table 2. Treatment-related acute toxicity according to the Nation-
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etaxel was also an effective regimen (10, 11). Recently, the
relation between radiosensitization and the inhibition of onco-
gene products, such as, H-ras and c-erbB-1, has been the focus
of attention (12, 13).
The selection of ideal candidates for CRT is another impor-
tant issue for successful bladder-preserving treatment. Some
studies have been undertaken to identify clinical factors that
help distinguish candidates for trimodality treatment. Rodel
et al. concluded that the completeness of TURBT is one of
the most potent factors of survival after CRT for patients with
invasive bladder cancer (14). In our patients with complete
TURBT, the rate of CR was 87.5% and the 5-yr disease-spe-
cific and overall survivals were 71.6% and 53.5%, respective-
ly. Our patients with complete TURBT were found to be more
likely to respond to CRT and to have a higher survival rate
than the 4 patients with incomplete TURBT. These findings
are comparable with those of other studies on CRT, which
achieved overall survivals of 45-60% (7, 14-16). Other clin-
ical factors that have been considered when choosing patients
for bladder preserving surgery include; small tumor size (<5
cm), early tumor stage, absence of ureteral obstruction, and
no evidence of pelvic lymph node metastases (7). In addition
to clinical factors, several promising molecular markers, such
as p53, bcl-2, bax, and pRB may help predict response to
specific cytotoxic therapies (17-19).
In terms of the timing of evaluating initial response to CRT,
there are two strategies, i.e., early and delayed evaluation. In
our study, delayed evaluation was performed at 4 weeks post-
CRT. In a study by Erlangen and several others, responses were
evaluated 4 to 6 weeks post-CRT by restaging TURBT (1-3).
Conversely, according to the Massachusetts General Hospital
(MGH) and Radiation Therapeutic Oncology Group (RTOG)
protocols, response evaluation should be performed much
earlier, i.e., after approximately 40 Gy of induction radiation
therapy (20-22). In the literature, salvage cystectomy plays
an important role in patients with a persistent tumor after
CRT. In this study, we also preferentially recommended cys-
tectomy, but the majority of patients with a persistent tumor
at initial evaluation after CRT refused a salvage operation.
Thus, we performed cystectomy as a salvage treatment in only
1 of the 5 patients with a persistent tumor at initial evalua-
tion after CRT. In the Erlangen series, which used a late-
response evaluation at 4 to 6 weeks post-CRT (1-3), the dis-
ease-specific survival rate at 5 yr for patients treated by sal-
vage cystectomy for invasive relapse was 51%. Similarly, in
the Boston series, the 5-yr disease-specific survival rate for
patients that ultimately underwent salvage cystectomy, but
after early-response evaluation, was approximately 50% (23).
Thus, available findings reveal no difference in survival after
salvage cystectomy according to the time of initial evalua-
tion after CRT.
In our subjects, 4 of 15 patients that achieved CR at initial
evaluations after CRT developed a recurrent tumor at the pre-
served bladder. Of these 4 patients, 2 had a superficial cancer
and 2 had an invasive cancer. Two patients with superficial
recurrence were easily managed by TURBT and survived with
bladder preservation at the time of analysis. Of two patients
with superficial recurrence, one patient showed experienced a
single recurrence at 48 months post-CRT. Moreover, 3 of 15
patients that achieved CR at initial evaluations after CRT devel-
oped isolated distant metastasis. Thus, close follow-up of pati-
ents after organ-preserving treatment is mandatory in patients
who achieve CR at initial evaluations after CRT for a long time.
Generally, 30% of patients who achieved initial CR after CRT
developed a recurrent tumor in the preserved bladder, and
about a half of these recurrent cancer were superficial (7).
We found that the common acute side effects by CRT are
transient diarrhea and voiding symptoms (frequency and urgen-
cy), which were common but easily managed with support-
ive treatment. Moreover, these symptoms usually resolved
within 2 or 3 weeks of completing treatment. In this study,
55% and 35% of patients experienced voiding symptoms
and diarrhea, respectively. At the time of analysis, no patient
required cystectomy for bladder contraction by radiation, but
in the largest series conducted to date by Erlangen, 2% of
patients required cystectomy for bladder shrinkage, 10% re-
ported some degree of incontinence or increased micturition
frequency, and 1.5% of patients experienced a late gastroin-
testinal toxicity (bowel obstruction) requiring surgical inter-
vention (14).
The present study is limited by the small number of patients
recruited, which is why we could not analyze results with res-
pect to clinical factors, especially the completeness of TURBT.
A study with a greater number of patients is required to iden-
tify factors that distinguish candidates for bladder-preserving
treatment. In our study, we could not perform salvage cystec-
tomy on patients with a persistent tumor after CRT, and num-
ber of patients with incomplete TURBT was too small to reach
the conclusion of survival differences with respect to the com-
pleteness of TURBT. However, considering that salvage cys-
tectomy was performed in only 2 patients, 5-yr disease-spe-
cific and overall survivals for the 16 patients with complete
TURBT were better than those reported by large studies in
the US and Europe (1-4). Furthermore, the 5-yr overall sur-
vival rate was comparable to the results of radical cystectomy
from large surgical series, which showed 48% from the Uni-
versity of Southern California and 45% from Memorial Sloan-
Kettering Cancer Center (24).
The trimodality treatment was found to be an effective
treatment option for patients with a muscle-invasive blad-
der cancer who underwent complete TURBT. Close follow-
up of patients after CRT is mandatory even in those patients
who achieved CR at initial response evaluations.
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